Alpha-radiation Imaging for Neuroendocrine Tumors

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Yusuf Menda

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.

Eligibility Criteria

Adults over 18 with well-differentiated neuroendocrine tumors, confirmed by pathology, that are positive for somatostatin receptors and measurable on imaging. Participants must be able to consent, follow study procedures, have a good performance status, and not have severe illnesses or conditions affecting study compliance.

Inclusion Criteria

I can take care of myself and perform daily activities.

I am 18 years old or older.

I have a tumor positive for somatostatin receptors, confirmed by a PET/CT scan within the last year.

+5 more

Exclusion Criteria

Individuals who are pregnant or breast feeding. A pregnancy test will be administered to individuals of child-bearing potential (per institutional policies) at screening. Individuals must agree to pregnancy tests prior to each administration of a radionuclidic agent for this study.

Individuals of reproductive potential who decline to use effective contraception through the study (22 days equaling 10 half-lives).

I haven't taken any experimental drugs in the last 4 weeks.

+5 more

Participant Groups

[203Pb]VMT-α-NET is being tested to see if it can identify neuroendocrine tumors using SPECT/CT imaging. This trial is the preliminary step before testing alpha radiation therapy for these types of tumors.

1Treatment groups

Experimental Treatment

Group I: [203Pb]VMT-α-NET SPECT/CTExperimental Treatment2 Interventions

injection of \[203Pb\]VMT-α-NET with serialized imaging and dosimetry measurements